Propanc Biopharma, Inc.

Investors

Financials

v3.26.3
Consolidated Balance Sheets
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
CURRENT ASSETS:    
Cash $ 832,006 $ 12,088
GST tax receivable 13,694 5,302
Prepaid expenses - current portion 7,661,967 8,334,046
Other current assets 34,923 1,380
TOTAL CURRENT ASSETS 8,542,590 8,352,816
Deferred offering costs 291,773
Prepaid expenses - long-term portion 4,190,543 10,925,835
Security deposit - related party 2,074 1,971
Operating lease right-of-use assets, net - related party 40,790 59,413
Property and equipment, net 3,915
TOTAL ASSETS 12,779,912 19,631,808
CURRENT LIABILITIES:    
Accounts payable 1,131,429 1,249,596
Accrued expenses and other payables 855,350 1,486,550
Accrued interest 128,318 190,795
Notes payable, net of discount 543,312
Convertible notes, net of discounts and including put premiums 537,921
Operating lease liability - related party, current portion 24,489 17,664
Embedded conversion option liabilities 403,892
Employee benefit liability 754,038 667,901
TOTAL CURRENT LIABILITIES 3,354,433 5,578,240
NON-CURRENT LIABILITIES:    
Loan payable - long-term - related party, net of discount 105,627
Operating lease liability - long-term portion - related party 23,818 41,749
TOTAL NON-CURRENT LIABILITIES 23,818 147,376
TOTAL LIABILITIES 3,378,251 5,725,616
Commitments and Contingencies (See Note 9)
STOCKHOLDERS’ EQUITY:    
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 3,310,827 and 464,471 shares issued and outstanding as of June 30, 2026 and 2025, respectively 3,310 464
Common stock issuable (487,939 and 310 shares as of June 30, 2026 and 2025, respectively) 487
Additional paid-in capital 152,752,314 138,254,808
Accumulated other comprehensive income 1,176,255 1,318,917
Accumulated deficit (144,484,230) (125,621,520)
Treasury stock ($0.001 share) (46,477) (46,477)
TOTAL STOCKHOLDERS’ EQUITY 9,401,661 13,906,192
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 12,779,912 19,631,808
Series A Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY:    
Preferred stock, value
Series B Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY:    
Preferred stock, value
Series C Preferred Stock [Member]    
STOCKHOLDERS’ EQUITY:    
Preferred stock, value 2
Nonrelated Party [Member]    
CURRENT LIABILITIES:    
Loans payable 65,280
Related Party [Member]    
CURRENT LIABILITIES:    
Accrued interest 28,318 56,935
Loans payable 460,809 415,329
Operating lease liability - related party, current portion 24,489 17,664
NON-CURRENT LIABILITIES:    
Loan payable - long-term - related party, net of discount 0 105,627
Operating lease liability - long-term portion - related party $ 23,818 $ 41,749

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL
v3.26.3
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
REVENUE    
Revenue
OPERATING EXPENSES    
Administration expenses 670,607 108,950
Compensation and related taxes 2,275,937 23,296,390
Professional and consulting expenses 14,572,616 33,622,510
Occupancy expenses - related party 40,932 26,560
Research and development 625,477 223,721
TOTAL OPERATING EXPENSES 18,185,569 57,278,131
LOSS FROM OPERATIONS (18,185,569) (57,278,131)
OTHER INCOME (EXPENSE)    
Interest expense (430,539) (563,757)
Interest income 161 9
Derivative expense (333,596)
Change in fair value of derivative liabilities 13,709 212,450
Change in fair value of warrant liability (99,695)
Other expense (6,000)
Settlement expense (320,000)
Gain (loss) on extinguishment of debt, net 133,071 (871,032)
Foreign currency transaction gain (loss) 32,152 (89,243)
TOTAL OTHER INCOME (EXPENSE), NET (677,141) (1,645,169)
LOSS BEFORE TAXES (18,862,710) (58,923,300)
Tax benefit
NET LOSS (18,862,710) (58,923,300)
Deemed Dividend (932,246)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (19,794,956) $ (58,923,300)
BASIC NET LOSS PER SHARE $ (17.62) $ (371.22)
DILUTED NET LOSS PER SHARE $ (17.62) $ (371.22)
BASIC WEIGHTED AVERAGE SHARES OUTSTANDING 1,123,709 158,727
DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING 1,123,709 158,727
OTHER COMPREHENSIVE INCOME (LOSS)    
Unrealized foreign currency translation gain (loss) $ (142,662) $ 49,336
TOTAL OTHER COMPREHENSIVE INCOME (LOSS) (142,662) 49,336
TOTAL COMPREHENSIVE LOSS $ (19,937,618) $ (58,873,964)

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL
v3.26.3
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (18,862,710) $ (58,923,300)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:    
Issuance of common stock for services 4,993,748 51,348,000
Stock based settlement 75,000
Amortization of prepaid stock based expenses 8,498,492 4,621,230
Foreign currency transaction loss (gain) (32,152) 89,243
Depreciation expense 997
Amortization of debt discounts 210,076 303,563
Amortization of right-of-use assets 21,706 20,187
Change in fair value of derivative liabilities (13,709) (212,450)
Change in fair value of warrant liability 99,695
Derivative expense 333,596
Loss (gain) on extinguishment of debt, net (133,071) 871,032
Non-cash interest expense 6,781 5,519
Accretion of put premium 37,450
Changes in Assets and Liabilities:    
GST receivable (8,117) (2,405)
Prepaid expenses (41,121) 1,379
Other current assets (33,471)
Accounts payable (183,012) 187,732
Employee benefit liability 51,476 40,184
Accrued expenses and other payables (401,049) 677,889
Accrued interest 44,545 255,155
Operating lease liability (14,189) (21,722)
NET CASH USED IN OPERATING ACTIVITIES (5,682,635) (405,168)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of equipment (4,933)
NET CASH USED IN INVESTING ACTIVITIES (4,933)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from convertible promissory notes, net of original issue discounts and issue costs 100,000 222,500
Proceeds from issuance of the initial preferred shares of Series C Preferred stock, net of issuance cost included as temporary equity 950,099
Proceeds from exercise of Series C warrants 3,000,000
Repayment of convertible notes (203,350) (8,000)
Repayment of notes (671,777) (122,788)
Repayment of loans payable - related party (185,381)
Proceeds from the sale of common stock, net of offering costs 3,314,458
Proceeds from note payable 75,000 320,000
Proceeds from loans payable - related parties 78,249 343,700
Deferred offering costs (264,656)
NET CASH PROVIDED BY FINANCING ACTIVITIES 6,457,298 490,756
Effect of exchange rate changes on cash 50,188 (94,585)
NET INCREASE (DECREASE) IN CASH 819,918 (8,997)
CASH AT BEGINNING OF YEAR 12,088 21,085
CASH AT END OF YEAR 832,006 12,088
Cash paid during the year:    
Interest 131,687 30,715
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities    
Reduction of put premium related to conversions of convertible notes 114,399 10,229
Conversion of convertible notes and accrued interest to common stock 476,335 79,686
Settlement of accounts payable for shares of common stock 129,354
Settlement of loans to former director for shares of common stock 74,395
Settlement of loans payable including accrued interest for shares of common stock 125,765 86,248
Deferred offering cost charged to additional paid in capital upon closing of offering 291,773
Issuance of common stock related to debt exchange agreement 125,765
Debt discounts related to derivative liability 222,500
Operating lease right-of-use asset and operating lease liability pursuant to ASC 842 62,126
Issuance of common stock and common stock issuable for prepaid services (net of amortized portion) 885,554 19,259,880
Deemed dividend related to Series C Preferred Stock 932,246
Reclassification of warrant liability into equity upon conversions and reclassifications 982,040
Reclassification of temporary equity into permanent equity upon amendment of Series C Preferred designation $ 1,000,000

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL

Sign up for email alerts

Be the first to receive breaking news

Sign up today